Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues

Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response. TP53 (tumor protein p53) is a tumor suppressor gene frequently mutated in cancer an...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Alex M., Boichard, Amélie, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012180/
https://www.ncbi.nlm.nih.gov/pubmed/31564192
http://dx.doi.org/10.1080/15384047.2019.1665956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012180/
https://www.ncbi.nlm.nih.gov/pubmed/31564192
http://dx.doi.org/10.1080/15384047.2019.1665956

Ejemplares similares